NNNN NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Anbio Biotechnology Class A Ordinary Shares · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 10.61 USD
7.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -52.0% below the Trend Line and sits at 5.0% of its 52-week range. The latest completed week returned 7.2%, after a 13.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.

Setup score 29 out of 100
Latest Close 10.61 USD 7 Aug 2026
1W Return 7.2% latest completed week
4W Return 13.0% short-term follow-through
12W Return -60.6% quarterly tape
Trend Breadth 13.5% 7 of 52 weeks active
Volume Ratio 1.5x vs 13-week average
What is working
  • Next-week expectancy is positive at 57.71% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 7.2% Latest completed week; four-week move 13.0%. Indicator stack 7/32 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.71% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 43 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -52.0% below the Trend Line and sits at 5.0% of its 52-week range. The latest completed week returned 7.2%, after a 13.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1012-week average 0.21

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 13.0% over four weeks, -60.6% over 12 weeks, and -79.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W7.2%
4W13.0%
12W-60.6%
26W-58.6%
52W-79.2%
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.97Latest activity-pressure read.
Pressure change-10.4%Four-week change in activity pressure.
Leadership-66.07Latest relative-leadership reading.
RS change10.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 79%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength1/100Blend of value, momentum, and quality. Underlying universe rank 100; rank 1 is best.
Value2/100Relative valuation strength. Underlying universe rank 99; rank 1 is best.
Quality26/100Profitability and accounting quality. Underlying universe rank 75; rank 1 is best.
Momentum1/100Medium-term price momentum. Underlying universe rank 100; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
72.7x
Price divided by trailing earnings.
Price / sales
53.9x
Market value relative to trailing revenue.
EV / EBITDA
79.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
87.2%
Gross profit retained from each unit of revenue.
Operating margin
66.7%
Operating profit retained from revenue.
Free-cash-flow margin
-77.9%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.6%
Net share repurchases relative to market value.
Shareholder yield
-1.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 43 relevant articles.

14 positive · 27 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-80.7%Distance below the 52-week high.
13-week volatility16.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 269 weeks finished lower.
Best week+20.7%Week of 22 May.
Worst week-33.2%Week of 5 Jun.
Latest week+7.2%Week of 7 Aug.

Shape of recent returns

Strong gains11
Modest gains5
Flat weeks1
Modest losses0
Sharp losses9
Recent vol16.2%13-week weekly-return volatility.
Base vol16.7%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew10.9% / -12.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.10; No reversal markers Next-Week ExpectancyPositive 57.71%

Next-week expectancy is positive with a 57.71% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors7/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 78; Small Cap Core rank 99 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 43 relevant articles.

Anbio Biotechnology (NNNN) Earnings Forecast: Future EPS & Revenue Growth Estimates Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202610.61 USD7.2%22.12 USD23.92 USD-0.97-66.07281.7KOff
31 Jul 20269.90 USD0.0%22.93 USD24.09 USD-1.03-67.79251.5KOff
24 Jul 20269.90 USD4.3%23.58 USD24.28 USD-1.08-68.48142.4KOff
17 Jul 20269.49 USD1.1%24.37 USD24.48 USD-0.97-71.17161.5KOff
10 Jul 20269.39 USD-26.1%25.13 USD24.68 USD-0.88-73.42271.2KOff
3 Jul 202612.70 USD-12.6%25.78 USD24.90 USD-0.72-64.47156.9KOff
26 Jun 202614.53 USD-12.7%26.59 USD25.07 USD-0.44-59.76494.9KOff
19 Jun 202616.64 USD6.7%26.89 USD25.22 USD-0.18-56.5991.2KOff
12 Jun 202615.59 USD-32.2%27.13 USD25.34 USD0.12-58.36205.8KOff
5 Jun 202622.99 USD-33.2%27.47 USD25.49 USD0.28-37.06173.1KOff
29 May 202634.41 USD5.8%27.28 USD25.52 USD0.34-9.4977.5KOff
22 May 202632.52 USD20.7%26.69 USD25.39 USD0.32-10.95125.0KOff
15 May 202626.94 USD4.3%26.37 USD25.28 USD0.19-24.4792.2KOff
8 May 202625.84 USD-10.6%26.44 USD25.25 USD0.03-27.13145.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context